Scinai Immunotherapeutics (SCNI) Consolidated Net Income (2014 - 2024)

Scinai Immunotherapeutics has disclosed Consolidated Net Income across 11 years of filings, most recently posting -$2.3 million for Q4 2024.

• Consolidated Net Income for Q4 2024 came in at -$2.3 million, down 24.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.7 million (up 83.51% YoY), and the FY2025 annual result was -$9.7 million, down 12.82% from the prior year.
• Consolidated Net Income came in at -$2.3 million for Q4 2024 at Scinai Immunotherapeutics, down from $11.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $55.9 million in Q3 2020 to a low of -$19.9 million in Q1 2020.
• The 5-year median for Consolidated Net Income is -$1.8 million (2023), against an average of $779736.8.
• Across the five-year window, Consolidated Net Income jumped 405.05% in 2020 and sank 1755.58% in 2023, its largest moves.
• Scinai Immunotherapeutics' Consolidated Net Income stood at -$11.4 million in 2020, then surged by 238.61% to $15.7 million in 2021, then tumbled by 221.3% to -$19.1 million in 2022, then surged by 90.46% to -$1.8 million in 2023, then retreated by 24.14% to -$2.3 million in 2024.
• The last three Consolidated Net Income figures came in at -$2.3 million (Q4 2024), $11.0 million (Q3 2024), and -$5.9 million (Q2 2024), per Business Quant data.